ReviewACS biomaterials science & engineering2025
Metal-Based Categorization of Recent Metal Organic Frameworks with Application in Bone Disease Treatment.
Review in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preparation optimization, structural characterization, stability and promoting calcium absorption mechanism of sturgeon cartilage peptide-calcium chelates.Food chemistry: X · 2026Article
- Bibliometric and visualized analysis of metal‒organic frameworks in bone tissue engineering and bone diseases.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in metal-organic frameworks (MOFs) have transformed the field of bone disease treatment by offering multifunctional platforms that integrate targeted drug delivery, enhanced osteogenesis, and antibacterial properties within a single material system. This review categorizes contemporary MOFs based on their metal constituents, such as zinc, magnesium, zirconium, cobalt, calcium, iron, copper, titanium, and rare earth metals, emphasizing their distinct physicochemical properties and unique biological functionalities. Unlike traditional biomaterials, MOFs provide highly tunable pore architectures and exceptional surface areas for efficient drug encapsulation and controlled release, facilitating localized therapeutic effects with minimal invasiveness. Cutting-edge developments include one-pot synthesis methods that enable the uniform distribution of therapeutic agents and sustained release profiles, significantly improving clinical applicability. This perspective highlights the synergistic effects of MOFs combined with scaffolds, hydrogels, and implants, which promote cellular proliferation, osteogenic differentiation, and angiogenesis, thus addressing critical challenges in bone regeneration. Moreover, emerging insights into metal ion-specific mechanisms such as calcium signaling in osteogenesis, zinc-mediated angiogenesis, and the antibacterial role of copper and rare earth elements underscore the strategic design of MOFs tailored to complex bone pathologies, including osteoporosis, infections, and osteosarcoma. This comprehensive overview not only maps recent progress but also delineates future research directions to optimize MOF functionality and expedite its translation into clinical bone therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.